---
action_items:
- id: 12783ad91ab4
  severity: writing
  text: Add a dedicated 'Ethics and Broader Impact' section addressing dual-use risks,
    specifically for Life Science (Drug/Clinic) domains.
- id: 3470fb889e4f
  severity: writing
  text: Clarify data privacy and consent procedures for 'Clinic' tasks in EywaBench
    to ensure compliance with medical data standards.
artifact_hash: 6f6f16bf33fe17a682df44afbf900ee0d80c1586f03954b67f158a9d54f94900
artifact_path: projects/PROJ-573-https-arxiv-org-abs-2604-27351/paper/metadata.json
backend: dartmouth
feedback: ''
github_authenticated: false
model_name: qwen.qwen3.5-122b
prompt_version: 1.1.0
reviewed_at: '2026-06-07T08:05:00.540668Z'
reviewer_kind: llm
reviewer_name: paper_reviewer_safety_ethics
score: 0.0
verdict: minor_revision
---

This review focuses exclusively on safety and ethics considerations regarding the proposed Eywa framework and the EywaBench benchmark.

**Safety and Dual-Use Concerns:**
The paper claims utility gains in "Life Science" domains, specifically "Drug" and "Clinic" sub-domains (Table 1, Section 5.1). Automating scientific discovery in these areas carries inherent dual-use risks. The framework enables heterogeneous agents to collaborate on tasks that could potentially accelerate the design of pharmaceutical compounds or clinical decision-making. However, the manuscript lacks a dedicated discussion on how these capabilities might be misused or how safeguards are implemented to prevent harmful applications (e.g., biosecurity risks). The "Limitation" section (Appendix) addresses computational cost and model quality but omits societal impact or misuse potential entirely. A "Broader Impact" or "Ethics Statement" section is required to contextualize these risks, consistent with standard AI safety guidelines.

**Data Privacy and Consent:**
EywaBench aggregates data from multiple sources, including tasks in the "Clinic" domain (Appendix, Section "EywaBench Details"). While the paper cites public benchmarks (MMLU-Pro, TabArena), it does not explicitly confirm that all aggregated clinical or medical data were anonymized or that IRB approval/consent was obtained for the benchmark construction. Given the sensitivity of clinical data, the authors must clarify the data provenance and privacy safeguards for these specific tasks to ensure compliance with ethical standards for medical AI.

**Recommendation:**
The technical contribution is sound, but the ethical framing is incomplete. Please revise the manuscript to include a discussion on dual-use risks associated with the Life Science capabilities and provide explicit statements regarding data privacy and consent for sensitive domains. These additions are necessary to ensure responsible dissemination of the work.
